Paige and Leica Biosystems Partner to Expand Access to Computational Pathology Products for Pathology and Oncology Research

On April 22, 2021 Paige, a global leader in AI-based digital diagnostics, and Leica Biosystems, a globally recognized cancer diagnostics and workflow solution leader, reported a strategic partnership to expand access to computational pathology products for clinical and translational research (Press release, Paige AI, APR 22, 2021, View Source [SID1234578378]). The partnership brings Paige’s AI-enabled research software for tumor detection, grading and quantification to Leica Biosystems digital pathology platform in select countries throughout North America and Europe.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The companies will collaborate to streamline and accelerate research workflows in pathology and oncology for higher quality, improved consistency and faster throughput. Leica Biosystems will distribute Paige’s research-use-only (RUO) computational pathology products, starting with Paige Prostate RUO, that identify areas of interest in tumor tissue and help researchers quantify and subtype tissue more efficiently and objectively. This software will be paired with Leica Biosystems digital pathology platform including slide image scanners and image management software. Additional detection efforts will focus on other indications.

"We are excited to partner with Leica Biosystems in our mutual goal to define the future of cancer research through the expanded access of computational pathology products for research," said Leo Grady, Ph.D., Chief Executive Officer of Paige. "By combining our proprietary software with the reliability of Leica hardware, we can better serve the research needs of the pathology community as it undergoes a rapid digital transformation."

"We are very excited about this collaboration with Paige. Our goal is to provide our customers with the tools that they need to continue to advance research and ultimately patient care," said Christopher Riley, President of Leica Biosystems. "Paige’s AI-powered solutions are central to this effort."